ArticleJournal of inflammation research2025
Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Splenic flexure colon cancer may represent a distinct prognostic subtype associated with elevated systemic inflammation and impaired nutritional status.Frontiers in immunology · 2026Article
- Preoperative Prediction of High Mitotic Count in Gastrointestinal Stromal Tumors Using CT Features and Serologic Indicators: An Interpretable Model with Multicenter External Validation.Journal of inflammation research · 2026Article
- Immunomodulatory effect of betulin and its derivatives on IL-6 expression in colorectal cancer cell lines and molecular docking insights.Frontiers in molecular biosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop and validate an integrated inflammatory prognostic index and to investigate associations between primary tumor location, chronic inflammatory status, adjuvant chemotherapy response, and survival outcomes in stage II-III colorectal cancer (CRC). Patients and Methods: A total of 1413 stage II-III CRC patients who underwent radical resection were enrolled and divided into discovery and validation cohorts. Preoperative systemic inflammatory biomarkers were quantified, and patients were followed for 3 years to establish an optimal chronic inflammatory index (CII) and evaluate its association with survival and chemotherapy efficacy across primary tumor locations. Results: The comprehensive CII was the top-performing prognostic biomarker, with time-dependent AUCs of 0.71(95% CI: 0.68-0.74) for 36-month RFS and 0.74(95% CI: 0.70-0.77) for OS. Furthermore, the 3C (CII, CEA and CA19-9) combined score demonstrated prognostic predictive AUCs of 0.74(95% CI: 0.71-0.77) for RFS and 0.76(95% CI: 0.72-0.79) for OS in the overall population. The splenic flexure and ascending colon showed significantly elevated CII levels versus other subsites, and the disease was divided into the proximal colon, transverse colon, distal colon and rectum. A significant CII gradient emerged across subsites (proximal > transverse > distal > rectal), with corresponding survival decrements (log-rank Conclusion: The validated CII represents a biologically relevant, subsite-specific prognostic biomarker in CRC. The chronic inflammation-based tumor subsite classification correlated with chemotherapy efficacy and clinical outcomes, highlighting its potential for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.